CHMP gives Pradaxa new contraindication, limits long-term use of calcitonin medicines
This article was originally published in Scrip
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has added Sanofi's antiarrythmic drug Multaq (dronedarone) to the list of contraindicated medicines associated with Boehringer Ingelheim’s anti-coagulant Pradaxa (dabigatran etexilate). Systemic ketoconazole, cyclosporine, itraconazole and tacrolimus are also contraindicated.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.